Researchers Develop Biomaterial to Shield Insulin Cells

A new lab-created coating mimics human egg cells to protect transplanted insulin-producing cells from immune rejection.

Updated on Oct. 16, 2026 in Diabetes

Bold flat-color editorial illustration of a spherical cell cluster encased in a protective membrane, representing medical bio-engineering advancements. — Researchers at The Pennsylvania State University developed a hydrogel biomaterial that shields transplanted insulin cells from immune rejection, potentially eliminating immunosuppressant drugs. AI Illustration. Upload story photo >

Live Poll

Do you trust lab results for medical treatments before they reach human clinical trials?

Researchers at The Pennsylvania State University have developed a biomaterial coating that shields transplanted insulin-producing cells from the recipient's immune system. This development could eliminate the need for immunosuppressant drugs in diabetes treatment.

Why it matters

The coating allows transplanted cells to survive and function without triggering an immune attack, addressing a major barrier in islet transplantation for diabetes patients. By avoiding the need for long-term immunosuppression, the technology could significantly reduce risks associated with such procedures.

The study involved a 20-micrometer-thick biomaterial coating constructed from fibrinogen and alginate. This structure successfully maintained normoglycemia in 80 percent of immunocompetent diabetic mice for 66 days.

The players

The Pennsylvania State University

This public research university served as the primary institution where the research team developed the new biomaterial coating.

Nature Biomedical Engineering

This peer-reviewed scientific journal published the findings from the research team regarding the new insulin-shielding technology.

The details

The team created the hydrogel structure by using thrombin on cell membranes to break down fibrinogen, creating a coating that mimics the protective zona pellucida of a human egg. This 20-micrometer layer acts as a barrier against the immune system while allowing necessary cell functions to continue.

Researchers began testing donor cell encapsulation for diabetes in the 1980s.
The team spent eight years finetuning the coating protocol between 2018 and 2026.
80 percent of mice maintained normoglycemia for 66 days post-transplantation.
One mouse maintained normoglycemia for more than 100 days during the study.
Researchers are currently working to improve the material's efficacy.

The Big Picture

This research marks a significant departure from the historical reliance on chronic immunosuppression in organ transplantation by enabling immune-protected cell delivery. It represents a potential paradigm shift toward cell-based therapies that minimize side effects for patients.

This development could eventually provide a safer treatment option for patients with diabetes by removing the requirement for powerful immunosuppressant medications. It aims to improve the long-term viability and success of islet cell transplant procedures.

The takeaway

This breakthrough demonstrates that engineering materials to mimic human biology can successfully bypass complex immune responses. Future research will focus on extending the duration of normoglycemia beyond the 100-day milestone observed in the best-case study outcomes.